It was recommended that she remain off CML-directed therapy with frequent PCR monitoring for BCR-ABL transcripts since she has a documented deep molecular response for more than two years. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.